NCT01602900View on ClinicalTrials.gov

Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 22, 2011

Primary Completion Date

April 12, 2012

Study Completion Date

April 12, 2012

Conditions

Huntington Disease

Interventions

DRUG

GSK356278

Investigational Medicinal Product

DRUG

Rolipram

Challenge Agent

Trial Locations (2)

NW10 7EW

GSK Investigational Site, London

W12 ONN

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01602900 - Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease | Biotech Hunter | Biotech Hunter